Inhalation Sciences (ISAB) announced that its CRO division, Inhalation Research Services (IRS), has signed an agreement with “an innovative US pharma company that is developing novel mRNA therapies for the treatment of cystic fibrosis and other pulmonary diseases” for a proof-of-concept project utilizing ISAB’s PreciseInhale aerosol generating system.
The contract, worth €101,000, is the first for the company’s new mouse exposure module and the first since ISAB signed agreements in April 2021 to expand its US business. The US company is expected to purchase a PreciseInhale system along with the mouse exposure module if the study is successful.
According to ISAB, the new in vivo mouse module involves tracheal intubation of the mice, allowing for direct delivery of the aerosol to the lung and producing good correlation to clinical deposition data. In May 2021, the company announced that it had received permission for a clinical trial of the PreciseInhale system.
ISAB CEO Manoush Masarrat commented, “We are delighted to start on this new partnership, the US is a hugely important market for us, and this is fantastic validation of the increased strategic sales and commercialization activities we’ve embarked on recently – with our lead generating partners in the US. It confirms yet again how much pharma companies can de-risk their research with our unique equipment. We look forward to our new relationships and partnerships in the US continuing to bear fruit.”
Read the Inhalation Sciences press release.
